The UK NICE has not recommended everolimus [Afinitor] as second-line treatment for advanced renal cell carcinoma.

Author:  

Publisher: Adis International

ISSN: 1173-5503

Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.627, 2011-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract